Luoxin Pharmaceuticals Group Stock Co.,Ltd. (002793.SZ) Issues Positive Earnings Forecast, Expects Q1-Q3 Net Profit of 22.7-25.2 Million Yuan, Achieving Turnaround

Stock News

2025/10/14

Luoxin Pharmaceuticals Group Stock Co.,Ltd. (002793.SZ) disclosed its performance forecast for the first three quarters of 2025. The company expects net profit attributable to shareholders to reach 22.7 million yuan to 25.2 million yuan, successfully turning from losses to profitability. Net profit after deducting non-recurring gains and losses is projected to be between 4.7 million yuan and 5.9 million yuan.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1150940510"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1150940510\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1150940510?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-14 19:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1150940510","market":"us","top_or_hot":-1,"title":"Luoxin Pharmaceuticals Group Stock Co.,Ltd. (002793.SZ) Issues Positive Earnings Forecast, Expects Q1-Q3 Net Profit of 22.7-25.2 Million Yuan, Achieving Turnaround","media":"Stock News","content":"<p>Luoxin Pharmaceuticals Group Stock Co.,Ltd. (002793.SZ) disclosed its performance forecast for the first three quarters of 2025. The company expects net profit attributable to shareholders to reach 22.7 million yuan to 25.2 million yuan, successfully turning from losses to profitability. Net profit after deducting non-recurring gains and losses is projected to be between 4.7 million yuan and 5.9 million yuan.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Luoxin Pharmaceuticals Group Stock Co.,Ltd. (002793.SZ) Issues Positive Earnings Forecast, Expects Q1-Q3 Net Profit of 22.7-25.2 Million Yuan, Achieving Turnaround</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLuoxin Pharmaceuticals Group Stock Co.,Ltd. (002793.SZ) Issues Positive Earnings Forecast, Expects Q1-Q3 Net Profit of 22.7-25.2 Million Yuan, Achieving Turnaround\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-10-14 19:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Luoxin Pharmaceuticals Group Stock Co.,Ltd. (002793.SZ) disclosed its performance forecast for the first three quarters of 2025. The company expects net profit attributable to shareholders to reach 22.7 million yuan to 25.2 million yuan, successfully turning from losses to profitability. Net profit after deducting non-recurring gains and losses is projected to be between 4.7 million yuan and 5.9 million yuan.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"08058","symbol_name":"罗欣药业","start_time":0,"source_url":"","article_id":"1150940510","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1150940510","pubTimestamp":1760440026,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Luoxin Pharmaceuticals Group Stock Co.,Ltd. (002793.SZ) disclosed its performance forecast for the first three quarters of 2025. The company expects net profit attributable to shareholders to reach...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"08058":"罗欣药业","002793":"罗欣药业","BK0239":"医药制造","BK0132":"高送转概念","BK0201":"可转债","BK0001":"水利水电建设"},"translate_title":"罗欣药业集团股份有限公司。（002793.SZ）发布正面盈利预告，预计Q1-Q3净利润2270-2520万元，实现扭亏为盈","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"08058":1,"002793":1},"content_text":"Luoxin Pharmaceuticals Group Stock Co.,Ltd. (002793.SZ) disclosed its performance forecast for the first three quarters of 2025. The company expects net profit attributable to shareholders to reach 22.7 million yuan to 25.2 million yuan, successfully turning from losses to profitability. Net profit after deducting non-recurring gains and losses is projected to be between 4.7 million yuan and 5.9 million yuan.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}